Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

MLA

Konopleva, Marina, et al. “Phase I/II Study of the Hypoxia-Activated Prodrug PR104 in Refractory/Relapsed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia.” Haematologica, vol. 100, no. 7, July 2015, pp. 927–34. EBSCOhost, https://doi.org/10.3324/haematol.2014.118455.

APA

Konopleva, M., Thall, P. F., Yi, C. A., Borthakur, G., Coveler, A., Bueso-Ramos, C., Benito, J., Konoplev, S., Gu, Y., Ravandi, F., Jabbour, E., Faderl, S., Thomas, D., Cortes, J., Kadia, T., Kornblau, S., Daver, N., Pemmaraju, N., Nguyen, H. Q., … Kantarjian, H. (2015). Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica, 100(7), 927–934. https://doi.org/10.3324/haematol.2014.118455

Chicago

Konopleva, Marina, Peter F Thall, Cecilia Arana Yi, Gautam Borthakur, Andrew Coveler, Carlos Bueso-Ramos, Juliana Benito, et al. 2015. “Phase I/II Study of the Hypoxia-Activated Prodrug PR104 in Refractory/Relapsed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia.” Haematologica 100 (7): 927–34. doi:10.3324/haematol.2014.118455.